Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Simulations Plus to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

BusinessWire_EN 
0 0 28.08.24
Simulations Plus to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference: https://mms.businesswire.com/media/20200318005128/en/780378/5/BusinessWireLogo.jpg
 

Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications for the biopharma industry, today announced that Shawn O’Connor, chief executive officer, will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference at the Marriott Marquis New York, on Friday, September 6, 2024. Mr. O’Connor will host one-on-one and small group meetings throughout the day.

This event is expected to include more than 200 companies as well as a preeminent group of investor attendees, including chief investment officers, portfolio managers and analysts. For more information about the conference, please visit the Morgan Stanley conference website.

About Simulations Plus

With more than 25 years of experience serving clients globally, Simulations Plus stands as a premier provider in the Biopharma sector, offering advanced software and consulting services that enhance drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. Our comprehensive biosimulation solutions integrate artificial intelligence/machine learning (AI/ML), physiologically based pharmacokinetics, physiologically based biopharmaceutics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. We also deliver simulation-enabled performance and intelligence solutions alongside medical communications support for clinical and commercial drug development. Our cutting-edge technology is licensed and utilized by leading pharmaceutical, biotechnology, and regulatory agencies worldwide. For more information, visit our website at www.simulations-plus.com. Follow us on LinkedIn | X | YouTube.

Environmental, Social, and Governance (ESG)

We focus our Environmental, Social, and Governance (ESG) efforts where we can have the most positive impact. To learn more about our latest initiatives and priorities, please visit our website to read our 2023 ESG update.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240828878863/en/

Simulations Plus Stock

€34.00
4.290%
A very strong showing by Simulations Plus today, with an increase of €1.40 (4.290%) compared to yesterday's price.
Simulations Plus is currently one of the favorites of our community with 6 Buy predictions and no Sell predictions.
With a target price of 51 € there is a positive potential of 50.0% for Simulations Plus compared to the current price of 34.0 €.
Show more
Like: 0
Share
BusinessWire_EN 
Business Wire, a Berkshire Hathaway company, is the global leader in press release distribution and regulatory disclosure. Investor relations, public relations, public policy and marketing professionals rely on Business Wire for secure and accurate distribution of market-moving news and multimedia.

Legal notice

Comments

Not a member yet? Sign up for free!